News

Molecular Analysis Pinpoints Potentially Important Pathways for Classical EDS

A gene expression analysis identified several deregulated pathways in fibroblasts from classical Ehlers-Danlos syndrome (EDS) patients, offering new insights for future studies investigating the disease mechanisms and potential therapies, a study reports. The study, “Molecular insights in the pathogenesis of classical Ehlers-Danlos syndrome from transcriptome-wide expression profiling of…

Excellagen, a Potential Treatment for EDS, is Poised for Launch

Generex Biotechnology will launch a wound care gel formulation called Excellagen, a potential treatment option for patients with Ehlers-Danlos syndrome (EDS) among others disorders. Excellagen is a highly-purified type 1 collagen-based, topical gel. According to Generex, its 3D dermal matrix favors wound healing. It activates platelets, leading to the…

Rising Healthcare Costs Strain EU Budgets Even as New Therapies Flourish

Cash-strapped governments across the 28-member European Union are struggling to control runaway healthcare expenditures — at exactly the same time as the promise of new but expensive therapies to treat rare diseases has never been greater. That’s the paradox faced by pharmaceutical companies as well as patient advocacy groups in…

Obstructive Sleep Apnea Is Common Among Children and Adolescents with Ehlers-Danlos Syndrome, Study Finds

Approximately two in five children and adolescents with Ehlers-Danlos syndrome experience impaired breathing during sleep, a condition called obstructive sleep apnea (OSA), a study reports. The condition increases daytime sleepiness and sleep-related breathing disorders, which reduce the quality of life. The study, “Obstructive Sleep Apnoea in Children and Adolescents…